Innovaderm Research, a Dual Focus CRO, Appoints Jeff Smith as New CEO
Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients.
Jeff brings nearly 30 years of experience in the pharmaceutical and CRO industry, most recently as CEO of another therapeutically focused CRO, where he has distinguished himself through his exceptional leadership, strategic vision, and ability to innovate. His expertise spans global operations, growth management, and fostering a collaborative and high-performing corporate culture. Jeff’s strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles.
Jeff is well-equipped to lead Innovaderm into its next phase of growth and innovation. Innovaderm is excited to add therapeutic expertise in rheumatology in addition to our world class dermatology research services, further expanding our capabilities and dedication to advancing medical knowledge and new therapies as a dual-focused CRO. Mr. Smith’s proven track record in organizational expansion and achieving meaningful and impactful results will be invaluable in driving these efforts forward.
“I am truly honored to join Innovaderm as CEO and collaborate with such a dedicated and talented team. Together, we are poised to work together with our sponsors to drive innovation in clinical research, making meaningful advancements in dermatology and rheumatology that will directly benefit patients and improve their quality of life.” Jeff Smith
Dr. Bissonnette, the founder of Innovaderm, remains as Executive Chairman, ensuring the CRO’s continuity and stability. His ongoing leadership will continue to guide Innovaderm’s mission to advance clinical research and improve patient outcomes. “I am confident Jeff Smith’s leadership will drive Innovaderm to new heights,” said Dr. Robert Bissonnette.
For more information about our dermatology and rheumatology resources please visit: https://innovaderm.com/
Innovaderm Research Inc.
Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials. With over 25 years of globally recognized expertise in dermatology and clinical operations, an extensive and continually expanding network of clinicians and sites, and a dedicated research clinic, Innovaderm offers a highly informed, focused, and comprehensive approach to addressing niche clinical needs in dermatology and rheumatology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203738867/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celonis Appoints Daniel Brown as Chief Product Officer to Drive Platform Innovation and Growth3.2.2025 16:38:00 CET | Press release
Brown brings over 25 years of product strategy and development experience across multiple domains of enterprise software Celonis, the global leader in Process Mining and Process Intelligence, today announced the appointment of Daniel Brown as Chief Product Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203013107/en/ Dan Brown joins Celonis as Chief Product Officer (Photo: Business Wire) “I am thrilled to join Celonis,” said Brown. “I’ve long admired its pioneering products, rapid innovation, and ability to deliver transformative results for customers and partners. What impresses me most is how the Celonis platform connects companies to their processes, teams to each other and AI to the business. I’m eager to contribute to this incredible journey and help shape the future of Process Intelligence.” “Dan brings a wealth of product strategy and leadership experience to Celonis,” said Alex Rinke, co-Founder and co-CEO
Michael Bowes Appointed Executive Vice President, Chief People Officer, The Estée Lauder Companies3.2.2025 16:10:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced that Michael Bowes has been appointed Executive Vice President, Chief People Officer, effective April 1, 2025, reporting directly to President and Chief Executive Officer, Stéphane de La Faverie. As the first company executive to hold the title of Chief People Officer, Michael will oversee all areas of Global Human Resources, including talent management, career development and organizational design, and, with a people-focused mindset, will drive the organization forward by focusing on continuous culture building. “Michael is a dynamic leader with a deep passion for people and culture,” said Stéphane. “His strategic vision, commitment to talent development, and ability to foster collaboration across our global organization make him the ideal leader to shape the future of our workforce. Michael’s promotion to EVP, Chief People Officer, reflects his exceptional track record and his unwavering commitment to making ELC a place where
ELIQUENT Life Sciences Announces: Rob Wojciechowski Named Chief Operations Officer3.2.2025 14:30:00 CET | Press release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the appointment of Rob Wojciechowski as Chief Operations Officer (COO). In this new role, Rob will oversee the company’s strategic initiatives across its regulatory, quality, and compliance practice areas, further positioning ELIQUENT to meet the growing global demand for integrated regulatory, quality, and safety solutions across diverse markets. “Rob’s expertise in building consulting practices and fostering client relationships aligns with ELIQUENT’s commitment to delivering innovative, high-quality solutions to meet the evolving needs of clients,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences. A seasoned life sciences executive and Non-Executive Director (NED) board member, Rob brings an extensive background in leadership, strategic consulting, and global business growth. As COO, Rob will work closely with the ELIQUENT leadership team to strengthen the fi
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing3.2.2025 14:00:00 CET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This milestone funding round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis.Additional support came from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others. Since its founding in June 2019, AdvanCell has grown from a belief in the potential of Targeted Alpha Therapy into a global organisation with 60 passionate team members, a 40,000-square-foot manufacturing facility, world-class pre-clinical infrastructure, a potentially best-in-class drug for prostate cancer that is in trials, and a deep and developing pipeline of assets. This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of de
Lenovo Named a Leader in Mid-Market Digital Transformation with Innovative Workplace Solutions3.2.2025 13:30:00 CET | Press release
Lenovo has been named a Leader in the 2024 Digital Workplace Services PEAK Matrix® Assessment for Mid-Market Enterprises by Everest Group. This recognition reflects Lenovo's innovative, customer-centric digital workplace solutions that empower mid-market enterprises to effectively navigate current-day business challenges. Empowering Mid-Market Enterprises with Lenovo’s Digital Workplace Solutions As businesses face increasing demands for cost-efficiency and operational agility, Lenovo’s Digital Workplace Solutions stand out for their ability to deliver personalized, scalable, and impactful results. Leveraging its proprietary Care of One™ platform, Lenovo delivers tailored experiences that enhance employee productivity, streamline IT operations, and reduce costs. Care of One™ Benefits Enhances user experience by up to 30% Reduces end-user support costs by 30% Helps resolve 40% of issues proactively through Gen AI-powered insights Through Care of One™, Lenovo enables hyper-personalized w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom